Clinical trial
Evaluating Genes in Sputum to Measure Drug Response in COPD
NCT00233051 · National Jewish Health, Other · Terminated
Key facts
| NCT number | NCT00233051 |
|---|---|
| Title | Evaluating Genes in Sputum to Measure Drug Response in COPD |
| Official title | Expression of Inflammatory Mediators in Induced Sputum: A Potential Biomarker of Drug Response in COPD |
| Lead sponsor | National Jewish Health, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Terminated |
| Study type | Interventional |
| Conditions | Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis |
| Intervention type | Drug |
| Interventions | Salmeterol or Salmeterol/Fluticasone |
| Enrollment | 20 |
| Start date | Apr 1, 2003 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Oct 5, 2005 |
| Last update posted | Mar 29, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: